{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2018:646T7SVEGPSEXHYTQGQ4QEYLZE","short_pith_number":"pith:646T7SVE","canonical_record":{"source":{"id":"1811.09718","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-11-23T22:15:45Z","cross_cats_sorted":[],"title_canon_sha256":"43bc365e73114b04020fdca500432f0839e7c8a066ae81d13ea34ee956572a2d","abstract_canon_sha256":"2ce2923469e50a5d36a934e564fe55cf53cb896d377b3455836c72131ca51fd0"},"schema_version":"1.0"},"canonical_sha256":"f73d3fcaa433e44b9f1381a1c8130bc903f5becc3a9bd67a247e7ea70034d1d4","source":{"kind":"arxiv","id":"1811.09718","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1811.09718","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"arxiv_version","alias_value":"1811.09718v1","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1811.09718","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"pith_short_12","alias_value":"646T7SVEGPSE","created_at":"2026-05-18T12:32:08Z"},{"alias_kind":"pith_short_16","alias_value":"646T7SVEGPSEXHYT","created_at":"2026-05-18T12:32:08Z"},{"alias_kind":"pith_short_8","alias_value":"646T7SVE","created_at":"2026-05-18T12:32:08Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2018:646T7SVEGPSEXHYTQGQ4QEYLZE","target":"record","payload":{"canonical_record":{"source":{"id":"1811.09718","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-11-23T22:15:45Z","cross_cats_sorted":[],"title_canon_sha256":"43bc365e73114b04020fdca500432f0839e7c8a066ae81d13ea34ee956572a2d","abstract_canon_sha256":"2ce2923469e50a5d36a934e564fe55cf53cb896d377b3455836c72131ca51fd0"},"schema_version":"1.0"},"canonical_sha256":"f73d3fcaa433e44b9f1381a1c8130bc903f5becc3a9bd67a247e7ea70034d1d4","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:00:01.410923Z","signature_b64":"h04raBisCez5D2szx1UyeoDqrxk8+KFeqUqIZLSQ+u7idGJhIB8THGIDsHfJvEF8rkY5Rd2e9qLmn5gO2cKSCw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"f73d3fcaa433e44b9f1381a1c8130bc903f5becc3a9bd67a247e7ea70034d1d4","last_reissued_at":"2026-05-18T00:00:01.410483Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:00:01.410483Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1811.09718","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:00:01Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"ZfxOb8aHBzmYZb3GSNfYg2xf1rL8bemfTsQPjzPPPxbQ9NCFR8Wb5cmfrMxzVqWza+3C8yrFHkxNkotCSvPaDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-03T15:37:23.954943Z"},"content_sha256":"4c8da3244bb455d3803ffe321d82080047314c9bea2290e50f9ba8ba3104a3b9","schema_version":"1.0","event_id":"sha256:4c8da3244bb455d3803ffe321d82080047314c9bea2290e50f9ba8ba3104a3b9"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2018:646T7SVEGPSEXHYTQGQ4QEYLZE","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Overview of Current Type I/II Kinase Inhibitors","license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.MN","authors_text":"Philip E. Bourne, Zheng Zhao","submitted_at":"2018-11-23T22:15:45Z","abstract_excerpt":"Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more kinase-related diseases. Currently, 42 kinase drugs have been approved by the FDA, most of which (39) are Type I/II inhibitors. Notwithstanding these advances, it is desirable to target additional kinases for drug development as more than 200 diseases, particularly cancers, are directly associated with aberrant kinase regulation and signaling. Here, we review the extant Type I/II drugs systematically to obtain insights into the binding pocket charac"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1811.09718","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:00:01Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"3DmtSewm5YeKEfTfN8TguqmF3q3ae8FenX2PJA1qc/AG2lWlp97MrtRvyruJ5yw3LywN9fZyLCTvXO5tIKEkDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-03T15:37:23.955518Z"},"content_sha256":"b8c81ad7cdea6e3e2a04f4b1379c3b5eff368a954065890e3a91534fee42ecc1","schema_version":"1.0","event_id":"sha256:b8c81ad7cdea6e3e2a04f4b1379c3b5eff368a954065890e3a91534fee42ecc1"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/bundle.json","state_url":"https://pith.science/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-06-03T15:37:23Z","links":{"resolver":"https://pith.science/pith/646T7SVEGPSEXHYTQGQ4QEYLZE","bundle":"https://pith.science/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/bundle.json","state":"https://pith.science/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/state.json","well_known_bundle":"https://pith.science/.well-known/pith/646T7SVEGPSEXHYTQGQ4QEYLZE/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2018:646T7SVEGPSEXHYTQGQ4QEYLZE","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"2ce2923469e50a5d36a934e564fe55cf53cb896d377b3455836c72131ca51fd0","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-11-23T22:15:45Z","title_canon_sha256":"43bc365e73114b04020fdca500432f0839e7c8a066ae81d13ea34ee956572a2d"},"schema_version":"1.0","source":{"id":"1811.09718","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1811.09718","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"arxiv_version","alias_value":"1811.09718v1","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1811.09718","created_at":"2026-05-18T00:00:01Z"},{"alias_kind":"pith_short_12","alias_value":"646T7SVEGPSE","created_at":"2026-05-18T12:32:08Z"},{"alias_kind":"pith_short_16","alias_value":"646T7SVEGPSEXHYT","created_at":"2026-05-18T12:32:08Z"},{"alias_kind":"pith_short_8","alias_value":"646T7SVE","created_at":"2026-05-18T12:32:08Z"}],"graph_snapshots":[{"event_id":"sha256:b8c81ad7cdea6e3e2a04f4b1379c3b5eff368a954065890e3a91534fee42ecc1","target":"graph","created_at":"2026-05-18T00:00:01Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more kinase-related diseases. Currently, 42 kinase drugs have been approved by the FDA, most of which (39) are Type I/II inhibitors. Notwithstanding these advances, it is desirable to target additional kinases for drug development as more than 200 diseases, particularly cancers, are directly associated with aberrant kinase regulation and signaling. Here, we review the extant Type I/II drugs systematically to obtain insights into the binding pocket charac","authors_text":"Philip E. Bourne, Zheng Zhao","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-11-23T22:15:45Z","title":"Overview of Current Type I/II Kinase Inhibitors"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1811.09718","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:4c8da3244bb455d3803ffe321d82080047314c9bea2290e50f9ba8ba3104a3b9","target":"record","created_at":"2026-05-18T00:00:01Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"2ce2923469e50a5d36a934e564fe55cf53cb896d377b3455836c72131ca51fd0","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-sa/4.0/","primary_cat":"q-bio.MN","submitted_at":"2018-11-23T22:15:45Z","title_canon_sha256":"43bc365e73114b04020fdca500432f0839e7c8a066ae81d13ea34ee956572a2d"},"schema_version":"1.0","source":{"id":"1811.09718","kind":"arxiv","version":1}},"canonical_sha256":"f73d3fcaa433e44b9f1381a1c8130bc903f5becc3a9bd67a247e7ea70034d1d4","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"f73d3fcaa433e44b9f1381a1c8130bc903f5becc3a9bd67a247e7ea70034d1d4","first_computed_at":"2026-05-18T00:00:01.410483Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T00:00:01.410483Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"h04raBisCez5D2szx1UyeoDqrxk8+KFeqUqIZLSQ+u7idGJhIB8THGIDsHfJvEF8rkY5Rd2e9qLmn5gO2cKSCw==","signature_status":"signed_v1","signed_at":"2026-05-18T00:00:01.410923Z","signed_message":"canonical_sha256_bytes"},"source_id":"1811.09718","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:4c8da3244bb455d3803ffe321d82080047314c9bea2290e50f9ba8ba3104a3b9","sha256:b8c81ad7cdea6e3e2a04f4b1379c3b5eff368a954065890e3a91534fee42ecc1"],"state_sha256":"6fa6e5c031d225c14ef9a9eb0625ba94050cb37c337c59af23ccefeab2d3a4f3"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"lihw6/zN/50L+NLzuMLmiI1CyMthHtti15+iARuiRVeLgCmMM0U7trxnwI1DNTUf52j/SpRf7dmzMRZcqAm3Dw==","signed_message":"bundle_sha256_bytes","signed_at":"2026-06-03T15:37:23.959434Z","bundle_sha256":"1f64933015a0f32b4aaf40a3607e70ef32b7575f2487641d43b344e2428c4edd"}}